PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25831967-0	2015	Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): enhancing serotonin release by combining serotonin (5HT) transporter inhibition with actions at 5HT receptors (5HT1A, 5HT1B, 5HT1D, 5HT7 receptors).	Vortioxetine	51-63	5-hydroxytryptamine receptor 1D	Homo sapiens	216-221	
26358483-1	2016	Vortioxetine is a new antidepressant, which mechanism of action is multimodal, targeting the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT3, 5-HT7 receptors and the serotonin transporter (5-HTT).	Vortioxetine	0-12	5-hydroxytryptamine receptor 1D	Homo sapiens	109-115	
34964415-5	2022	EXPERT OPINION: Vortioxetine is the first antidepressant that has shown improvements both in depression and cognitive symptoms, due to the unique multimodal mechanism of action that combine the 5-HT reuptake inhibition with modulations of other key pre- and post-synaptic 5-HT receptors (agonism of 5-HT1A receptor, partial agonism of 5-HT1B receptor, and antagonism of 5-HT3, 5-HT1D and 5-HT7 receptors).	Vortioxetine	16-28	5-hydroxytryptamine receptor 1D	Homo sapiens	377-383	
26879252-7	2016	Compared to the SSRIs, vortioxetine is defined as a multimodal antidepressant drug since it is not only a serotonin reuptake inhibitor, but also a 5-HT1D, 5-HT3, 5-HT7 receptor antagonist, 5-HT1B receptor partial agonist and 5-HT1A receptor agonist.	Vortioxetine	23-35	5-hydroxytryptamine receptor 1D	Homo sapiens	147-153	
25418918-4	2014	Vortioxetine is an agonist of 5-HT1A, a partial agonist of 5-HT1B and an antagonist of 5-HT1D, 5-HT3 and 5-HT7 serotoninergic receptors.	Vortioxetine	0-12	5-hydroxytryptamine receptor 1D	Homo sapiens	87-93	
25166025-1	2014	Vortioxetine (Brintellix( ), 1-[2-(2,4-dimethylphenyl-sulfanyl)-phenyl]-piperazine) is a multimodal antidepressant targeting the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT3, 5-HT7 receptors and the serotonin (5-HT) transporter (5-HTT).	Vortioxetine	0-12	5-hydroxytryptamine receptor 1D	Homo sapiens	145-151	
25166025-1	2014	Vortioxetine (Brintellix( ), 1-[2-(2,4-dimethylphenyl-sulfanyl)-phenyl]-piperazine) is a multimodal antidepressant targeting the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT3, 5-HT7 receptors and the serotonin (5-HT) transporter (5-HTT).	Vortioxetine	14-24	5-hydroxytryptamine receptor 1D	Homo sapiens	145-151	
25166025-1	2014	Vortioxetine (Brintellix( ), 1-[2-(2,4-dimethylphenyl-sulfanyl)-phenyl]-piperazine) is a multimodal antidepressant targeting the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT3, 5-HT7 receptors and the serotonin (5-HT) transporter (5-HTT).	Vortioxetine	29-82	5-hydroxytryptamine receptor 1D	Homo sapiens	145-151	
24311349-4	2014	In vitro studies indicate that vortioxetine is an inhibitor of the 5-HT transporter and is a 5-HT(1D), 5-HT3 and 5-HT7 receptor antagonist, a 5-HT(1A) receptor agonist and a 5-HT(1B) receptor partial agonist.	Vortioxetine	31-43	5-hydroxytryptamine receptor 1D	Homo sapiens	93-100	
25717481-8	2014	Vortioxetine is a novel antidepressant with a unique mechanism of action: it acts through the serotonine reuptake inhibition, but works also as 5HT(1A) agonist, as well as partial agonist of the 5HT(1B) receptor and antagonist of the 5HT(1D), 5HT(3) and 5HT(7) receptors.	Vortioxetine	0-12	5-hydroxytryptamine receptor 1D	Homo sapiens	234-240